New heart device tested in japan: no leads inside the heart
NCT ID NCT07091916
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study tested a new type of implantable defibrillator (EV ICD) in 14 Japanese patients with dangerous heart rhythms. The device is placed under the skin, outside the heart and blood vessels, to deliver a shock if a life-threatening rhythm occurs. Researchers checked if the device could safely stop induced abnormal rhythms and whether there were any major complications within two weeks of implant.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Extravascular implantable cardioverter defibrillator (EV ICD) device
- What this could lead to
- If successful, this device could offer a new way to protect people at risk of dangerous heart rhythms without leads inside the heart or blood vessels.
- What could go wrong
- This was a very small, early study in just 14 people, so results may not apply to everyone. The device is still new and long-term safety and performance are not yet fully known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
14 people
The number who actually took part.
- Started
-
Feb 2023
- Finished
-
Jan 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient has a Class I or IIa indication for implantation of an ICD according to the ACC/AHA/HRS Guidelines \[i\], or ESC guidelines \[ii\]. * Patient is at least 18 years of age and meets age requirements per local law. * Patient is geographically stable and willing and able to complete the study procedures and visits for the duration of the follow-up. \[i\] Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Hlatky MA, Granger CB, Hammill SC, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias. \[ii\] Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliot PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen DJ. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal 2015 36:41 (2793-2867). https://doi.org/10.1093/eurheartj/ehv316 Exclusion Criteria: * Patient is unwilling or unable to personally provide Informed Consent. * Patient has indications for bradycardia pacing \[iii\] or Cardiac Resynchronization Therapy (CRT) \[iv\] (Class I, IIa, or IIb indication). * Patient with an existing pacemaker, ICD, or CRT device implant or leads. * Patients with these medical interventions are excluded from participation in the study: * Prior sternotomy * Any prior medical condition or procedure that leads to adhesions in the anterior mediastinal space (i.e., prior mediastinal instrumentation, mediastinitis) * Prior abdominal surgery in the epigastric region * Planned sternotomy * Prior chest radiotherapy Or any other prior/planned medical intervention not listed that precludes their participation in the opinion of the Investigator. * Patient has previous pericarditis that: * Was chronic and recurrent, or * Resulted in pericardial effusion \[v\], or * Resulted in pericardial thickening or calcification \[vi\]. * Patients with these medical conditions or anatomies are excluded from participation in the study: * Hiatal hernia that distorts mediastinal anatomy * Marked sternal abnormality (e.g., pectus excavatum) * Decompensated heart failure * COPD with oxygen dependence * Gross hepatosplenomegaly Or any other known medical condition or anatomy type not listed that precludes their participation in the opinion of the Investigator. * Patients with a medical condition that precludes them from undergoing defibrillation testing: * Severe aortic stenosis * Intracardiac LA or LV thrombus * Severe proximal three-vessel or left main coronary artery disease without revascularization * Hemodynamic instability * Unstable angina * Recent stroke or transient ischemic attack (within the last 6 months) * Known inadequate external defibrillation * LVEF \<20% * LVEDD \>70 mm Or any other known medical condition not listed that precludes their participation in the opinion of the Investigator. * Patient with any evidence of active infection or undergoing treatment for an infection. * Patient is contraindicated from temporary suspension of oral/systemic anticoagulation * Patient with current implantation of neurostimulator or any other chronically implanted device that delivers current in the body. * Patient meets ACC/AHA/HRS or ESC clinical guideline Class III criteria for an ICD (e.g., life expectancy of less than 12 months). * Patient is enrolled or planning to enroll in a concurrent clinical study that may confound the results of this study, without documented pre-approval from a Medtronic study manager. * Patient with any exclusion criteria as required by local law (e.g., age or other). * Pregnant women or breastfeeding women, or women of child bearing potential and who are not on a reliable form of birth regulation method or abstinence. \[iii\] 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing). \[iv\] ACC/AHA/HRS guidelines for Cardiac Resynchronization Therapy. \[v\] As documented on echo or MRI. \[vi\] As documented on CT scan or MRI.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Tachycardia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medtronic Japan Co., Ltd.
Tokyo, 1080075, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Armband heart tracker takes on holter monitors
- Heart scans may unlock hidden risks in minority communities
- Could a short course of steroids calm a dangerous heart rhythm?
- Can we safely skip the shock test during heart device implant?
- Old gout drug may tame deadly heart inflammation
- Which sedation is best for cataract surgery? new trial aims to find out